335 related articles for article (PubMed ID: 19636023)
1. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
Stephenson AJ; Kattan MW; Eastham JA; Bianco FJ; Yossepowitch O; Vickers AJ; Klein EA; Wood DP; Scardino PT
J Clin Oncol; 2009 Sep; 27(26):4300-5. PubMed ID: 19636023
[TBL] [Abstract][Full Text] [Related]
2. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
3. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
4. Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?
Wæhre H; Vlatkovic L; Cvancarova M; Paus E; Fosså SD; Danielsen HE
Scand J Urol; 2014 Apr; 48(2):123-30. PubMed ID: 23885810
[TBL] [Abstract][Full Text] [Related]
5. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
6. Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Eggener SE; Scardino PT; Walsh PC; Han M; Partin AW; Trock BJ; Feng Z; Wood DP; Eastham JA; Yossepowitch O; Rabah DM; Kattan MW; Yu C; Klein EA; Stephenson AJ
J Urol; 2011 Mar; 185(3):869-75. PubMed ID: 21239008
[TBL] [Abstract][Full Text] [Related]
7. 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.
Mendhiratta N; Lee T; Prabhu V; Llukani E; Lepor H
Urology; 2015 Oct; 86(4):783-8. PubMed ID: 26163812
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Urol; 2004 Nov; 172(5 Pt 2):S42-6; discussion S46-7. PubMed ID: 15535442
[TBL] [Abstract][Full Text] [Related]
9. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
10. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
11. The association between pre-operative PSA and prostate cancer-specific mortality in patients with long-term follow-up after radical prostatectomy.
Lewinshtein D; Teng B; Valencia A; Gibbons R; Porter CR
Prostate; 2012 Jan; 72(1):24-9. PubMed ID: 21520159
[TBL] [Abstract][Full Text] [Related]
12. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
[TBL] [Abstract][Full Text] [Related]
14. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
15. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer-specific mortality after radical prostatectomy: value of preoperative MRI.
Woo S; Cho JY; Ku JH; Kim SY; Kim SH
Acta Radiol; 2016 Aug; 57(8):1006-13. PubMed ID: 26508791
[TBL] [Abstract][Full Text] [Related]
17. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.
Mossanen M; Nepple KG; Grubb RL; Androile GL; Kallogjeri D; Klein EA; Stephenson AJ; Kibel AS
Eur Urol Oncol; 2018 Jun; 1(2):143-148. PubMed ID: 31100238
[TBL] [Abstract][Full Text] [Related]
20. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
